WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...

Sarepta Therapeutics SRPT announced positive three-year top-line data from Part 1 of the phase III EMBARK study, evaluating ...

Dr. Mackey’s project, “ Regenerating healthy human skeletal muscle at single nucleus resolution ,” will create the most detailed molecular map to date of how healthy human muscle repairs itself. The ...

Keros Therapeutics KROS is a clinical-stage biopharmaceutical company developing innovative therapies for patients with ...

Surgical correction of scoliosis in patients with DMD remains controversial. This retrospective study enrolled patients who underwent posterior instrumented spinal fusion to correct spinal deformity ...

Your muscles need continuous maintenance to stay strong and healthy. Duchenne muscular dystrophy (DMD) happens when there is a change in a person's genetic instructions that affects the production of ...

After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.

A retrospective cohort study found that, among 459 patients with DMD, constipation (32.5%) was the most common GI complication, followed by dysphagia (9.4%). Older age, lower body mass index, and use ...

By Mariam Sunny Jan 26 (Reuters) - Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy slowed disease ...

Duchenne muscular dystrophy (DMD) is a genetic condition that causes increasing muscle weakness over time. While DMD currently has no cure, researchers are studying potential new treatments. When ...

From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and research. This year’s top stories on Duchenne muscular dystrophy (DMD) managed ...